Hot Stocks: FireEye Inc (NASDAQ:FEYE), Synageva BioPharma Corp (NASDAQ:GEVA), Intrexon Corp (NYSE:XON), Puma Biotechnology Inc (NYSE:PBYI)

FireEye, Inc. (NASDAQ: FEYE) filed a registration with the U.S. SEC to sell, from time to time, up to 13,282,316 shares of its Common Stock on behalf of Selling Shareholders. FireEye Inc (NASDAQ:FEYE) stock performance was 5.05% in last session and finished the day at $50.57. Traded volume was 6.04million shares in the last session and the average volume of the stock remained 3.61million shares. FireEye Inc (NASDAQ:FEYE) insider ownership is 7.00%.

Synageva BioPharma Corp (NASDAQ:GEVA) was upgraded by stock analysts at Wedbush from a “neutral” rating to an “outperform” rating in a report issued on Tuesday. The firm currently has a $93.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 9.68% from the company’s current price. Synageva BioPharma Corp (NASDAQ:GEVA) rose 8.02 percent to $84.09 Tuesday on volume of 6.04million shares. The intra-day range of the stock was $76.99 to $84.25. Synageva BioPharma Corp (NASDAQ:GEVA) has a market capitalization of $2.56billion.

MacroGenics, Intrexon Corp (NYSE:XON) and GlycoMimetics took advantage of national investor optimism to go public, a recent bio sell-off has seen each company’s shares shed signifiant value in recent weeks. Intrexon Corp (NYSE:XON)’s stock on Apr 22, 2014 reported a increase of 7.38% to the closing price of $21.10. Its fifty two weeks range is $17.52 -$38.50. The total market capitalization recorded $2.06billion. The overall volume in the last trading session was 1.41million shares. In its share capital, XON has 97.79million outstanding shares.

Equities research analysts at Citigroup Inc. initiated coverage on shares of Puma Biotechnology Inc (NASDAQ:PBYI) in a research note issued to investors on Monday. The firm set a “buy” rating and a $123.00 price target on the stock. On Tuesday, shares of Puma Biotechnology Inc (NYSE:PBYI) advanced 9.69% to close the day at $83.78. Company monthly performance is recorded as -26.43%. Puma Biotechnology Inc (NYSE:PBYI) quarterly revenue growth is -40.12%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone